Navigation Links
Bach Pharma Inc, Developing New Drug, GVT® to Treat Veterans Suffering from Gulf War Illness, and Millions of People Suffering from Neurodegenerative Diseases
Date:8/14/2019

Bach Pharma, Inc., a company based in North Andover, Massachusetts, is continuing its research and development of its drug platform GVT (Monosodium Luminol), created to treat and cure multiple neurodegenerative diseases including Gulf War Illness (GWI), ALS, and Parkinson’s disease among others. Overwhelming data from multiple animal studies have proven that GVT has the potential to help millions of people suffering from neurodegenerative diseases, specifically focusing on Veterans who suffer the effects of Gulf War Illness and related conditions.

In 2001, CEO Mark Henry, working with real estate developer Harold Brooks was able to recognize the immense potential for a drug platform they discovered while searching for drugs to help critically ill people survive. The major accomplishment for Henry was locating and bringing together eight founders were able to attract research institutions all over the world and convince them to work together to help mankind. While never intending to compete with the massive pharmaceutical corporations – the founders realized that this product, GVT, could make a huge difference to millions suffering the effects of Neurodegenerative Diseases. Henry recalls that, “What we experienced in the late 1990s was just short of a miracle. We continue to witness the powerful benefits from these products every day. With new data we discover new medical opportunities.”

Bach Pharma Inc’s primary medical product is GVT which is designed to act as a redox buffer in the patients’ brain cells – minimizing and potentially reversing the effects of Gulf War Illness in Veterans. As of 2019, it is believed that over 250,000 US Veterans suffer from some form of GWI and its associated complications including Parkinson’s disease and ALS.

Having successfully demonstrated effectiveness in several GWI animal models, Bach Pharma is in the midst of a $2.2M capital raise in order to fund the next stage of preclinical testing, specifically a toxicology study for the Veteran’s Administration. Individual Investors, Foundations and Veteran Organizations have already committed over $500,000 to this project. Once the toxicology studies are completed, Bach will qualify for an additional $8 million commitment from the US Department of Defense for additional testing of GVT.

COO Christopher LaFarge believes that GVT will be a safe and effective solution for the millions suffering from Neurodegenerative Diseases, “We have proven that neurodegenerative diseases, GWI, radiation exposure, and other related diseases share a common theme, namely oxidative stress, and that GVT has enormous potential to help millions live reasonably normal lives.”

About Bach Pharma, Inc.: Bach Pharma, Inc. (BACH), a privately held research and development pharmaceutical company, directs the development of therapies for degenerative neurological illnesses. The company’s lead candidate GVT is a novel cytoprotective agent that has powerful anti-oxidant and anti-inflammatory properties, which research has shown can reverse oxidative stress, restore intracellular redox homeostasis and quell inflammation. Due to its strong safety profile along with its ability to cross the retinal and the blood-brain barriers and enter cells of the central nervous system, GVT has the potential to treat serious diseases of the central nervous and immune systems and dramatically reduce the cost of global health care.
BACH is a proud member of the Massachusetts Biotechnology Council and a host company for the Massachusetts Life Science Center Internship Challenge.

Read the full story at https://www.prweb.com/releases/bach_pharma_inc_developing_new_drug_gvt_to_treat_veterans_suffering_from_gulf_war_illness_and_millions_of_people_suffering_from_neurodegenerative_diseases/prweb16499968.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related medicine technology :

1. Pharmagen Announces First Quarter 2013 Results
2. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
3. Aoxing Pharmaceutical Company, Inc. Announces Financial Results For Third Quarter Of 2013 Fiscal Year
4. Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeants Board of Directors
5. ViroPharma er stolt over at bakke op om HAE-dag :-) 2013 og vi hjælper HAE-patienter med at fylde verden med smil
6. RuiYi and Genor BioPharma Collaborate on Development in China of RYI-008, a Novel Therapeutic for Autoimmune Diseases and Cancer
7. RuiYi et Genor BioPharma collaborent au développement du RYI-008 en Chine, un nouveau traitement contre les maladies auto-immunes et le cancer
8. PharmaPoint: Multiple Sclerosis - United Kingdom Drug Forecast and Market Analysis to 2022
9. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
10. Access Pharmaceuticals Reports First Quarter Results
11. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2019)... ... August 17, 2019 , ... Inc. Magazine Unveils Its ... Ranks No. 2502 on the 2019 Inc. 5000 with Three-Year Revenue Growth of ... physician recruitment firm is No. 2502 on its annual Inc. 5000 list, the ...
(Date:8/16/2019)... (PRWEB) , ... August 16, 2019 , ... ... psychological service, Eye Movement Desensitization and Reprocessing therapy (EMDR). This therapeutic technique aims ... an evidence-based practice used for post-traumatic stress disorder (PTSD), depression, chronic pain, anxiety, ...
(Date:8/16/2019)... ... 2019 , ... The American Academy of Emergency Medicine Physician ... as a member group. , SBEP is a longstanding democratic group that has ... out the AAEM-PG for administrative and practice management support that will help preserve ...
Breaking Medicine Technology:
(Date:8/16/2019)... ... ... The clinical trial supply chain landscape is constantly shifting, and clinical professionals are expected ... Solutions Manager at Almac Clinical Services , Natalie Balanovsky, in a live ... journey through time as it relates to clinical trial supply. , She will ...
(Date:8/16/2019)... ... August 16, 2019 , ... Dr. Demetri Arnaoutakis, a board-certified ... Beauty Network. , The Haute Beauty Network, well known for its exclusive and ... hair restoration expert and our newest addition to the Haute Beauty members-only network. ...
(Date:8/15/2019)... (PRWEB) , ... August 15, 2019 , ... With many students either starting college for ... for this particular demographic. According to the CDC , “there are about 20 million ... are in people between the ages of 15 and 24. Young people are at greater ...
(Date:8/14/2019)... , ... August 14, 2019 , ... Teguar Corporation has ... in America. This list has long-been established as a mark of success for some ... Dell, and Oracle. Teguar made the list in 2015, 2016 and 2017. This year, ...
(Date:8/14/2019)... ... August 15, 2019 , ... R3 Stem Cell ... R3 Stem Cell International is offering regenerative procedures with mesenchymal stem cells performed ... procedure costs only $2950, which includes a complete IV therapy or two joint ...
Breaking Medicine News(10 mins):